Clinical analysis of 48 cases of malignant superior vena cava syndrome

Sun, Manzhen; Chen, Xiaoli; Li, Hongfei; Zhang, Xudong; Wang, Xiaofei; Zheng, Ruipan; Li, Guowen; Wang, Lin; Li, Dianyuan

doi:10.1186/s12957-021-02300-8

Cited by 7 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is worth noting that malignant tumor patients with superior vena cava obstruction syndrome generally have a poor prognosis, with a median survival period of only about 6 months [19]. In this study, among patients with superior vena cava obstruction syndrome who underwent 125 I radioactive particle brachytherapy, a symptom relief rate of 34.76% was achieved, and this complication was con rmed as an independent predictive factor for predicting overall survival time.…”

Section: Discussionmentioning

confidence: 58%

Nomogram Prediction Model for Overall Survival of Late-Stage Lung Cancer Patients Undergoing 125I Particle Implantation Brachytherapy

Ding,

Hao,

Wang

et al. 2024

Preprint

View full text Add to dashboard Cite

Objective The purpose of this study was to explore the overall survival rate of late-stage lung cancer patients after receiving 125I particle implantation brachytherapy and establish a corresponding Nomogram prediction model to provide reference for clinical decision-making. Methods We retrospectively analyzed 436 late-stage lung cancer patients who underwent 125I radioactive particle brachytherapy in the Department of Nuclear Medicine of the General Hospital of Northern Theater Command of the Chinese People's Liberation Army from December 2013 to June 2019. The 436 patients were randomly divided into a training set and a validation set in a 7:3 ratio, with 305 patients in the training set and 131 patients in the validation set. Single-factor and multivariate Cox proportional hazards models were used to select independent factors affecting the prognosis of late-stage lung cancer patients. Based on these factors, a nomogram model was constructed to predict the overall survival at 1, 3, and 5 years after 125I particle implantation brachytherapy for late-stage lung cancer, as well as the 1-year progression-free survival. The accuracy and predictive ability of the model were evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Results The 436 patients were included and randomly divided into the training and validation sets. The total survival time of the patients was 1113 ± 391.11 days, and the progression-free survival time was 200 ± 100.03 days. The results of the univariate and multivariate Cox proportional hazards model analyses of overall survival time (OS) showed that smoking, lung atelectasis, superior vena cava obstruction syndrome, and surgical time were significantly associated with the OS of the patients and were independent influencing factors. The results of the univariate and multivariate Cox proportional hazards model analyses of progression-free survival (PFS) showed that planning target volume, maximum dose, average dose, preoperative D90, V100 at 1 cm around the lesion, and surgical time were significantly associated with the PFS of the patients and were independent influencing factors. Based on these independent prognostic factors, nomogram models were constructed to predict the 1, 3, and 5-year overall survival and 1-year progression-free survival of late-stage lung cancer patients. The ROC curves showed that both the training and validation set nomogram prediction probabilities had good predictive ability. Decision curve results demonstrated good clinical applicability of the nomogram. The calibration curve showed a good correlation with the ideal curve, suggesting good accuracy of both models. Conclusion This study revealed the potential benefits of 125I particle implantation brachytherapy for the overall survival rate of late-stage lung cancer patients and provided clinicians with a reliable tool to personalize the assessment of patient prognosis and formulate treatment plans.

show abstract

Section: Discussionmentioning

confidence: 58%

Nomogram Prediction Model for Overall Survival of Late-Stage Lung Cancer Patients Undergoing 125I Particle Implantation Brachytherapy

Ding,

Hao,

Wang

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Due to the nature of SVCS, only retrospective data are available in the literature [ 20 ], mainly comprising small numbers of patients. In China 48 cases of varying malignant SVCS were reported to achieve symptom relief in only 50% (5/10 patients) in a radiotherapy alone and 54.5% (12/22 patients) in a chemoradiotherapy group [ 5 ]. RT doses ranged from 45 Gy/3-Gy fractions (fx) to 50 and above/2-Gy fx.…”

Section: Discussionmentioning

confidence: 99%

“…However, in rapidly evolving SVCS, e.g., due to massive tumor growth, most patients show distinctive symptoms [ 3 , 4 ]. These include, but are not limited to, shortness of breath (caused by compression or laryngeal and/or tracheal edema) and swelling of neck and face (due to increased blood volume and lymphostasis) [ 5 ]. Prolonged and/or rapidly increasing untreated SVCS can lead to cerebral edema, causing headache, confusion, apathy, and can ultimately lead to death [ 2 , 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Symptom relief, prognostic factors, and outcome in patients receiving urgent radiation therapy for superior vena cava syndrome

et al. 2022

View full text Add to dashboard Cite

Purpose Superior vena cava syndrome (SVCS) often results from external vessel compression due to tumor growth. Urgent symptom-guided radiotherapy (RT) remains a major treatment approach in histologically proven, rapidly progressive disease. Despite several publications, recent data concerning symptom relief and oncological outcome as well as potential confounders in treatment response are still scarce. Methods We performed a retrospective single-center analysis of patients receiving urgent RT between 2000 and 2021 at the University Medical Center Göttingen. Symptom relief was evaluated by CTCAE score during the RT course. Effects of variables on symptom relief were assessed by logistic regression. The impact of parameters on overall survival (OS) was evaluated using Kaplan–Meier plot along with the log-rank test and by Cox regression analyses. Statistically significant (p-value < 0.05) confounders were tested in multivariable analyses. Results A total of 79 patients were included. Symptom relief was achieved in 68.4%. Mean OS was 59 days, 7.6% (n = 6) of patients showed long-term survival (> 2 years). Applied RT dose > 39 Gy, clinical target volume (CTV) size < 387 ml, concomitant chemotherapy, and completion of the prescribed RT course were found to be statistically significant for OS; applied RT dose and completion of the prescribed RT course were found to be statistically significant for symptom relief. Conclusion Symptom relief by urgent RT for SVCS was achieved in the majority of patients. RT dose and completion of the RT course were documented as predictors for OS and symptom relief, CTV < 387 ml and concomitant chemotherapy were predictive for OS.

show abstract

“…At present, radiotherapy and chemotherapy are the best choices for unresectable malignant tumors. 55,56 Previous studies showed that the combination of phytochemicals and chemotherapy may improve the overall efficacy of cancer treatment and minimize toxicity. 57 Luteolin has been investigated as a potent chemopreventive agent for numerous types of cancers.…”

Section: Improve the Efficacy Of Radiotherapy And Chemotherapymentioning

confidence: 99%

Research Progress with Luteolin as an Anti-Tumor Agent

Cai

Mao

Wang

et al. 2022

Natural Product Communications

View full text Add to dashboard Cite

In this review, we outline the new expertise and research progress with luteolin as an antitumor agent, and clarify the related results from the aspects of tumor proliferation, apoptosis, invasion, metastasis, sensitivity to radiotherapy and chemotherapy, angiogenesis, and immunotherapy. In recent years, with the development of medical technology, the early detection rate of tumors has increased significantly. However, the number of cancer patients remains high. Therefore, a new and reasonably effective tumor therapeutic drug is urgently demanded. Luteolin, a flavonoid and widespread in nature, attracts more and more attention due to its universal biological utility, especially in the study of antitumor activity. This article reviews the work published in the past 20 years on the role and mechanism of luteolin as an antitumor agent, showing that this compound has a variety of effects for antitumor treatment by acting on different cytokines. Although clinical studies have not yet been widely carried out, a series of basic studies have confirmed that luteolin is a reasonably effective antineoplastic agent or anticancer adjuvant. Besides, derivatives of luteolin have good application prospects.

show abstract

Clinical analysis of 48 cases of malignant superior vena cava syndrome

Cited by 7 publications

References 29 publications

Nomogram Prediction Model for Overall Survival of Late-Stage Lung Cancer Patients Undergoing 125I Particle Implantation Brachytherapy

Nomogram Prediction Model for Overall Survival of Late-Stage Lung Cancer Patients Undergoing 125I Particle Implantation Brachytherapy

Symptom relief, prognostic factors, and outcome in patients receiving urgent radiation therapy for superior vena cava syndrome

Research Progress with Luteolin as an Anti-Tumor Agent

Contact Info

Product

Resources

About